BACKGROUND:Fatty liver disease(FLD)is increasingly recognized as one of the most common chronic liver diseases in China.This study aimed to investigate the prevalence and risk factors of FLD in Chengdu,Southwest China,and to provide a relevant basis for the prevention and intervention of FLD. METHODS:Altogether 9094 subjects(4721 men and 4373 women)of over 18 years old who had received a medical checkup in the West China Hospital of Sichuan University between January and December 2007 were evaluated for FLD.FLD was diagnosed by ultrasonography.Body mass index(BMI),height,body weight,blood pressure,fasting plasma glucose(FPG),triglycerides(TG),total cholesterol (TCh),alanine aminotransferase(ALT),hepatitis B surface antigen(HBsAg),high-density lipoprotein cholesterol (HDL-C),and low-density lipoprotein cholesterol(LDL-C) were measured using routine laboratory methods. RESULTS:The overall prevalence of FLD was 12.5%,which was more than 3-fold higher in males than in females (18.9%vs.5.7%,χ2=359.624,P<0.001).The prevalence increased with age in females and males of less than 50 years.The prevalence of alcoholic,suspected alcoholic,and non-alcoholic FLD was 2.6%,3.6%,and 6.3%,respectively. Multiple logistic regression analyses showed that 10 factors (male sex,age,BMI,FPG,hypertension,TG,TCh,HDL-C, LDL-C,and ALT abnormalities)were closely related to FLD. In heavy drinkers,obesity increased the risk of FLD by 23.78-fold(95%CI,10.22-55.33),but heavy drinking was only associated with a 2-fold(95%CI,1.50-2.66)increased risk in obese subjects.CONCLUSIONS:The prevalence of FLD among a health- checkup population in Chengdu,Southwest China was lower than the published for other areas of China.FLD in Chengdu adults was found to be closely associated with sex, age,BMI,and other metabolic syndrome features.
Li, HongWang, You-JuanTan, KeZeng, LiLiu, LiLiu, Feng-JunZhou, Tao-YouChen, En-QiangTang, Hong
目的观察乙肝病毒(hepatitis B virus,HBV)核酸疫苗pCMV-S2S免疫小鼠后的特异性细胞毒性T淋巴细胞(CTL)应答,及对表达HBV preS2S抗原的SP2/0-S2S肿瘤细胞攻击的保护作用。方法将BALB/c小鼠随机分为3组,于0、4及8周分别接种pCMV-S2S(实验组)、乙肝表面抗原蛋白疫苗(HBsAg,对照组1)、空载质粒(pCMV,对照组2)各3次。末次免疫后4周,每组各取3只小鼠,以乳酸脱氢酶(LDH)释放法检测特异性CTL活性。各组其它小鼠均用于肿瘤细胞攻击实验:分别于一侧胁部皮下种植SP2/0-S2S细胞,同时于另一侧种植不表达HBV preS2S抗原的SP2/0-CMV细胞作阴性对照。种植肿瘤细胞(荷瘤)后观察成瘤时间、肿瘤大小和荷瘤后小鼠的生存时间及生存率。结果pCMV-S2S组CTL活性为(34.21±1.38)%,高于HBsAg组〔(19.64±1.50)%〕和pCMV组〔(3.45±1.89)%〕(P<0.05)。荷瘤后10d,pCMV-S2S组小鼠SP2/0-S2S细胞的成瘤率为58.3%,低于SP2/0-CMV细胞的成瘤率(91.7%)(P<0.05);两对照组SP2/0-S2S细胞与SP2/0-CMV细胞的的成瘤率无明显差异。荷瘤后pCMV-S2S组初次出现死亡小鼠的时间为24d,较两对照组均延迟了13d,平均生存时间为(31±1)d,较两对照组延长(P<0.05);4周生存率(75%)高于两对照组(P<0.05),两对照组之间生存时间及生存率差异无统计学意义。结论HBV核酸疫苗pCMV-S2S能在小鼠体内诱生较强的特异性CTL活性,对荷瘤小鼠具有特异性免疫保护作用,可望用于HBV感染的免疫保护。
